Results 21 to 30 of about 7,800 (196)

Multifocal Infantile Hemangiomas Treated by Oral Itraconazole: A Case Report

open access: yesNepal Journal of Dermatology, Venereology & Leprology, 2022
We describe a case of a 2-month-old girl presented with more than 60 papules and nodules of hemangiomas involving the skin of the sclera, endocanthion, lower lip, and labium majus pudenda without visceral hemangiomas and laboratory abnormality.
Wei Wu   +6 more
doaj   +3 more sources

Results of Infantile Hemangioma Laser Therapy in Children with Persistent Residual Signs after Systemic Propranolol Therapy: Clinical Cases

open access: yesВопросы современной педиатрии, 2021
Background. Infantile hemangiomas are revealed in 1-3% of newborns and 10-12% of infants. There are only anecdotal reports on the laser therapy efficacy in this pathology management.
Tatyana S. Belysheva   +6 more
doaj   +1 more source

Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis [PDF]

open access: yes, 2014
Infantile hemangiomas (IHs) are non-malignant, largely cutaneous vascular tumors affecting approximately 5–10% of children to varying degrees. During the first year of life, these tumors are strongly proliferative, reaching an average size ranging from 2
AMAYA, CLARISSA   +10 more
core   +1 more source

Surgical treatment of infantile nasal and labial hemangioma in the involuted phase: a case report [PDF]

open access: yesRevista Brasileira de Cirurgia Plástica, 2020
Infantile hemangioma (IH) is the most common vascular tumor and the most frequent benign neoplasm in childhood, with the highest incidence in females and the white population.
Monique Mendes   +3 more
doaj   +1 more source

Long-term results of unilateral cleft lip repair with multiple infantile hemangiomas including one involving the cleft side of the upper lip

open access: yesArchives of Plastic Surgery, 2020
Infantile hemangiomas have a growth phase and an involution phase. For this reason, serial observation has generally been recommended as the treatment for uncomplicated infantile hemangiomas.
Dae Kyun Jeong   +3 more
doaj   +1 more source

Propranolol in the treatment of infantile haemangiomas:lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey [PDF]

open access: yes, 2015
Oral propranolol is widely prescribed as first line treatment for infantile haemangiomas (IHs) and anecdotally prescribing practice differs widely between ...
Audrain, H   +55 more
core   +2 more sources

Approach to infantile hemangiomas

open access: yesIndian Journal of Dermatology, 2016
Infantile hemangiomas are a group of vascular tumors and are considered to be one of the most common tumors in infancy. Ambiguity still prevails over its origin, etiopathogenesis, and optimal management.
Anil Abraham   +2 more
openaire   +3 more sources

Neurodevelopmental abnormalities in children with PHACE syndrome. [PDF]

open access: yes, 2012
Prior case reports have identified neurodevelopmental abnormalities in children with PHACE syndrome, a neurocutaneous disorder first characterized in 1996.
Barkovich, A James   +8 more
core   +1 more source

Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study

open access: yesThe Pan African Medical Journal, 2019
INTRODUCTION: Infantile hemangioma is the most common benign tumor in infancy. Currently, oral propranolol is the treatment of choice for infantile hemangioma, but there is no consensus when it comes to its recommended dosage for this condition.
Arun Prasad   +4 more
doaj   +1 more source

Infantile hemangioma in a V2 distribution: Treatment with nadolol

open access: yesJournal of Family Medicine and Primary Care, 2015
Infantile hemangiomas are common benign tumours of infancy affecting up to 10% of children. They are typically not present at birth but undergo a rapid proliferation stage and then plateau in growth before resolving spontaneously. Recently, beta-blockers
Mariah Giberson, Robert Hayes
doaj   +1 more source

Home - About - Disclaimer - Privacy